Cabaletta Bio Inc (CABA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.47-0.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CABA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress registrational RESET-Myositis trial with planned mid-2027 data and 2H27 BLA submission; initiate RESET-SSc registrational cohort in 4Q26.
Stated as a priority in 2 of last 2 quarters. Management reported registrational RESET-Myositis trial enrollment progressing with data expected mid-2027 to support a 2H27 BLA submission. Additionally, the RESET-SSc registrational cohort is planned to initiate in 4Q26. These milestones align with management's stated timelines and show delivering progress toward clinical development and regulatory filing goals.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Registrational RESET-Myositis clinical data on track to be reported in mid-2027 to support 2H27 BLA submission; SSc-associated ILD registrational study anticipated to initiate in 4Q26.”
“Patient enrollment progressing in registrational 17-patient dermatomyositis cohort; plans for BLA submission in 2027; SSc pivotal design anticipated 1H26.”
Broaden outpatient dosing option for rese-cel and incorporate preconditioning-free (PC-free) dosing across RESET clinical program based on favorable safety and emerging data.
Stated as a priority in 2 of last 2 quarters. Management emphasized expanding outpatient dosing and advancing preconditioning-free dosing cohorts across multiple RESET trials. Clinical data presentations and ongoing enrollment in higher-dose PC-free cohorts support active development, indicating delivering progress consistent with stated priorities.
“Expansion of outpatient dosing option with rese-cel remains a top priority; PC-free approach incorporated in RESET-MG and higher-dose cohorts enrolling in RESET-PV and RESET-SLE.”
“Presenting PC-free clinical data in RESET-PV and RESET-SLE; planning longer-term PC-free data and higher dose cohorts in 2H26; outpatient dosing option progressing.”
Implement automated manufacturing with Cellares under a 10-year commercial supply agreement to enable scalable, low-cost production of rese-cel.
Stated as a priority in 2 of last 2 quarters. Management executed a 10-year commercial supply agreement with Cellares and presented initial clinical data using Cellares-manufactured rese-cel. These actions demonstrate delivering progress on scalable automated manufacturing to support commercial supply.
“Announced 10-year commercial supply agreement with Cellares for automated manufacturing to supply thousands of rese-cel batches per year at low cost.”
“Closed underwritten offering to fund operations; initial clinical experience with Cellares-manufactured rese-cel presented at ASGCT 2026.”
Manage cash and capital to ensure funding of operating plan into mid-2027, supported by May 2026 registered direct offering proceeds.
Stated as a priority in 2 of last 2 quarters. Management reported cash and equivalents increased from $116.6 million at 2026-Q1 to $225.1 million at 2026-Q2, primarily due to the May 2026 registered direct offering. This cash position is expected to fund operations into mid-2027, indicating delivering financial resource management consistent with stated plans.
“Cash, cash equivalents and short-term investments of approximately $225.1 million as of June 30, 2026, expected to fund operating plan into mid-2027.”
“Cash, cash equivalents and short-term investments of $116.6 million as of March 31, 2026; proceeds from May 2026 offering expected to fund operations into mid-2027.”
Control research and development and general administrative expenses while advancing clinical programs.
Stated as a priority in 2 of last 2 quarters. R&D expenses increased from $37.4 million in 2026-Q1 to $44.4 million in 2026-Q2, reflecting clinical development activity. G&A expenses rose modestly from $6.9 million to $7.6 million. Expense trends align with advancing clinical programs, indicating managing operating expenses amid growth.
“Research and development expenses were $44.4 million; general and administrative expenses were $7.6 million for the three months ended June 30, 2026.”
“Research and development expenses were $37.4 million; general and administrative expenses were $6.9 million for the three months ended March 31, 2026.”
Over the trailing year it converted 0.91x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
10 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.